{"filing":{"accession_number":"0001193125-26-390539","cik":"0001808898","ticker":"BNTC","company_name":"Benitec Biopharma Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"bntc-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/bntc-20260914.htm"},"events":[{"id":33250,"run_id":30571,"accession_number":"0001193125-26-390539","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Benitec Biopharma issued a press release on September 14, 2026 announcing financial results for the fiscal year ended June 30, 2026, including consolidated balance sheets and statements of operations showing a net loss of $45.5 million and cash position of $180 million. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The filing includes both financial statements and operational updates on the company's lead clinical program BB-301.","company_name":"Benitec Biopharma Inc.","ticker":"BNTC","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36646,"accession_number":"0001193125-26-390539","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Benitec Biopharma issued a press release on September 14, 2026 announcing financial results for the fiscal year ended June 30, 2026, including consolidated balance sheets and statements of operations showing a net loss of $45.5 million and cash position of $180 million. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The filing includes both financial statements and operational updates on the company's lead clinical program BB-301.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:05:42.466889+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36646,"accession_number":"0001193125-26-390539","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Benitec Biopharma issued a press release on September 14, 2026 announcing financial results for the fiscal year ended June 30, 2026, including consolidated balance sheets and statements of operations showing a net loss of $45.5 million and cash position of $180 million. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The filing includes both financial statements and operational updates on the company's lead clinical program BB-301.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:05:42.466889+00:00","company_name":"Benitec Biopharma Inc.","ticker":"BNTC","filing_date":"2026-09-14"}]}